Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy

Clinical Transplantation

Volumn 29, Issue 12, 2015, Pages 1098-1104

  Nelson, Lærke M ^a   Penninga, Luit ^a   Villadsen, Gerda E ^b   Mølgaard, Henning ^b   Eiskjær, Hans ^b   Hillingsø, Jens G ^a   Rasmussen, Allan ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amyloidosis; Cardiomyopathy; Heart transplantation; Leu111Met; Liver transplantation; Mutation; Transthyretin

Indexed keywords

APROTININ; CORTICOSTEROID; LEUCINE; METHIONINE; MYCOPHENOLATE MOFETIL; PREALBUMIN; TACROLIMUS; TECHNETIUM 99M;

ADULT; AMYLOIDOSIS; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FAMILIAL TRANSTHYRETIN AMYLOIDOSIS; FEMALE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART SCINTISCANNING; HEART TRANSPLANTATION; HUMAN; ISOLATED LIVER; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; FOLLOW UP; GRAFT SURVIVAL; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84983140550     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12633     Document Type: Article

References (33)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997: 337: 898.
2. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005: 1753: 11.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003: 349: 583.
4. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003: 10: 160.
5. Husby G, Ranlov PJ, Sletten K, Marhaug G. The amyloid in familial amyloid cardiomyopathy of Danish origin is related to pre-albumin. Clin Exp Immunol 1985: 60: 207.
6. Nordlie M, Sletten K, Husby G, Ranlov PJ. A new prealbumin variant in familial amyloid cardiomyopathy of Danish origin. Scand J Immunol 1988: 27: 119.
7. Ranlov I, Alves IL, Ranlov PJ, Husby G, Costa PP, Saraiva MJ. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine 111 variant in serum from patients and carriers. Am J Med 1992: 93: 3.
8. Nordvag BY, Ranlov I, Riise HM, Husby G, el-Gewely MR. Retrospective molecular detection of transthyretin met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues. Hum Genet 1993: 92: 265.
9. Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J 1998: 19: 782.
10. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003: 254: 225.
11. Costa RH, Grayson DR, Darnell JE Jr. Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol 1989: 9: 1415.
12. Holmgren G, Ericzon BG, Groth CG et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993: 341: 1113.
13. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000: 6: 263.
14. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation 2004: 77: 64.
15. Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg 2007: 32: 180.
16. Raichlin E, Daly RC, Rosen CB et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009: 88: 219.
17. Wilczek HE, Larsson M, Ericzon BG. Long-term data from the familial amyloidotic polyneuropathy world transplant registry (FAPWTR). Amyloid 2011: 18(Suppl 1): 193.
18. Yamamoto S, Wilczek HE, Nowak G et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007: 7: 2597.
19. Schaadt BK, Hendel HW, Gimsing P, Jonsson V, Pedersen H, Hesse B. 99 mtc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003: 44: 177.
20. Minamimoto R, Kubota K, Ishii K et al. Re-evaluating the potentials and limitations of (99m)tc-aprotinin scintigraphy for amyloid imaging. Am J Nucl Med Mol Imaging 2013: 3: 261.
21. Glaudemans AW, Slart RH, Zeebregts CJ et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009: 36: 702.
22. Demetris AJ, Batts KP, Dhillon AP et al. Banff schema for grading liver allograft rejection. An international consensus document. Hepatology 1997: 25: 658.
23. Nelson LM, Penninga L, Sander K et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant 2013: 27: 203.
24. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997: 64: 74.
25. Okamoto S, Zhao Y, Lindqvist P et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011: 18: 200.
26. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 2012: 19(Suppl 1): 78.
27. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002: 73: 745.
28. Stangou AJ, Hawkins PN, Heaton ND et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998: 66: 229.
29. Yazaki M, Mitsuhashi S, Tokuda T et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007: 7: 235.
30. Yazaki M, Tokuda T, Nakamura A et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000: 274: 702.
31. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007: 14: 277.
32. Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990: 87: 2843.
33. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012: 93: 1017.